Comparative effectiveness and safety of sarilumab vs Janus kinase inhibitors in late- and younger-onset rheumatoid arthritis

Clicks: 2
ID: 316567
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #119 of 202 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Glucocorticoid (GC)- and methotrexate (MTX)-sparing strategies are clinically important in rheumatoid arthritis (RA), yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset-late-onset RA (LORA) vs young-onset RA (YORA)-also remains unclear. This study aimed to compare the effectiveness and safety of sarilumab and JAK inhibitors in patients with late- and younger-onset rheumatoid arthritis. METHODS: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation, and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. RESULTS: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. CONCLUSION: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.
Reference Key
openalex_W7163990134 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yuji Nozaki, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita1, Yumiko Wada, Takuya Kotani, Tohru Takeuchi, Toshihiko Hidaka, Shoichi Hino, Toshiaki Miyamoto, Hirofumi Miyake, Kazunari HATTA, K. Mamoto, Yutaro Yamada, Tadashi Okano, T. Okano, Jun Saegusa, Masahiro Horita, Keiichiro Nishida, Koji Kinoshita, Shinya Rai
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag289
URL
https://doi.org/10.1093/rheumatology/keag289
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.